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INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of 
severe vision loss in people aged over 50 and its prevalence increases 
exponentially after the age of 70(1,2). Although neovascular AMD is the 
most damaging form of the disease, dry AMD accounts for approxi-
mately 90% of all cases. Geographic atrophy (GA), the advanced non-
neo vascular form of AMD, accounts for 35% of all cases of late-stage 
AMD and 20% of legal blindness attributable to AMD(3). Intravitreal 
injection of anti-vascular endothelial growth factor (VEGF) agents has 
revolutionized the treatment and prognosis of neovascular AMD. Ho -
wever, dry AMD treatment still remains a challenge. Currently, the 
only approved treatment for dry AMD is the use of Age-Related Eye 
Disease Study (AREDS)-based vitamin supplements, which does not 
halt the vision loss but lowers the risk of developing advanced stages 
of AMD (either geographic atrophy or neovascular AMD) and reduces 
visual loss in people at risk for the disease. In addition, the AREDS 
formula does not prevent GA from forming or progressing(4,5).
Over the last years, a significant amount of research has been 
fo cusing on the physiopathology of dry AMD and new treatment 
approaches. However, research has been hampered by some issues, 
such as the multifactorial nature of dry AMD, its complex physiopa-
thology, the lack of an animal model for dry AMD, and the lack of in 
vitro systems for testing new drugs.
In this article, we will review dry AMD emerging treatments that 
have basically focused on two strategies: prevention of photorecep-
tors and retinal pigment epithelium (RPE) cells loss, and suppression 
of inflammation. The former can be achieved by neuroprotection in-
duction, oxidative damage prevention, and visual cycle modification 
(Table 1). Before getting into details on the drugs under research, the 
physiopathology of dry AMD will be presented.
Dry AMD AnD geogrAphic Atrophy pAthogenesis
The processes involved in dry AMD and GA pathogenesis are not 
completely understood. Current investigations suggest that oxida-
tion and inflammation play important roles in the pathogenesis of 
the diseases.
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a 
pri mary structural component of the human retina, comprising 60% 
of the polyunsaturated fatty acids in the retina. It is the most oxidi-
zable fatty acid in the body and is found in the membrane of the 
outer segment of the photoreceptors(6). The human macula has a 
li felong exposure to light and very high oxygen consumption. This 
mi croenvironment is highly permissive for the oxidative damage of 
reactive oxygen to DHA. DHA peroxidation generates lipofuscin, a 
yellow-brown pigment that represents undigested material from the 
oxidation of DHA. Lipofuscin cannot be degraded by the lysosomes 
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ABSTRACT
Emerging treatments for dry age-related macular degeneration (AMD) and geo -
gra phic atrophy focus on two strategies that target components involved in physio -
pathologi cal pathways: prevention of photoreceptors and retinal pigment epithe lium 
loss (neuro protection induction, oxidative damage prevention, and visual cycle 
mo dification) and suppression of inflammation. Neuroprotective drugs, such as 
ci liary neurotrophic factor, brimonidine tartrate, tandospirone, and anti-amyloid β 
antibodies, aim to prevent apoptosis of retinal cells. Oxidative stress and depletion of 
essential micronutrients are targeted by the Age-Related Eye Disease Study (AREDS) 
formulation. Visual cycle modulators reduce the activity of the photoreceptors and 
retinal accumulation of toxic fluorophores and lipofuscin. Eyes with dry age-related 
macular degeneration pre sent chronic inflammation and potential treatments in-
clude corticosteroid and com plement inhibition. We review the current concepts 
and rationale of dry age-rela ted macular degeneration treatment that will most 
likely include a combination of drugs targeting different pathways involved in the 
development and progression of age-related macular degeneration.
Keywords: Macular degeneration/drug therapy; Retina; Retinal pigment epithelium; 
Inflammation; Complement activation
RESUMO
Os novos tratamentos para a forma seca da degeneração macular relacionada à idade 
(DMRI) e da atrofia geográfica têm sido baseados em duas estratégias que abordam 
componentes envolvidos nos mecanismos fisiopatológicos da doença: prevenção da perda 
de fotorreceptores e células do epitélio pigmentado da retina (indução de neuroproteção, 
diminuição do dano oxidativo e modificação do ciclo visual) e supressão da inflamação. 
As drogas neuroprotetoras visam evitar a apoptose das células retinianas, como o fator 
neurotrófico ciliar, o tartarato de brimonidina, a tandosporina e anticorpos antiamiloide β. 
A redução do dano oxidativo e a complementação de micronutrientes essenciais são os 
objetivos da fórmula AREDS. Os modificadores do ciclo visual reduzem a atividade dos 
fotorreceptores e o acúmulo de fluoróforos tóxicos e lipofuscina na retina. Olhos com a 
forma seca da degeneração macular relacionada à idade apresentam inflamação crônica 
e os novos tratamentos incluem corticosteroides e inibidores do sistema complemento. 
Neste artigo, revisamos o estágio atual do tratamento da forma seca da degeneração ma­
cular relacionada à idade que provavelmente será feito através da combinação de drogas 
que agem em diferentes componentes envolvidos no aparecimento e na progressão da 
degeneração macular relacionada à idade.
Descritores: Degeneração macular/quimioterapia; Retina; Epitélio pigmentado da retina; 
Inflamação; Ativação do complemento
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in the retinal pigment epithelium (RPE) and accumulates within it, 
in creasing RPE lysosomal pH. Continuous lipofuscin formation along 
with pH change interfere with proper lysosomal enzymes function 
and impair their phagosomal activity(7). With time, RPE becomes over -
whelmed with cellular debris and vitamin A metabolites, such as A2-E 
(a toxic vitamin A dimer). When present in excessive levels, lipofuscin 
and A2-E damage photoreceptors and choriocapillaris, leading to 
geo graphic atrophy(8).
Besides being toxic to the RPE, A2-E has also been shown to acti -
vate the complement cascade(9,10). Complement system is part of the 
immune system called the innate immune system. It consists of ma ny 
small proteins in the blood and is a potent mechanism of host defen-
se against pathogens and abnormal cells. Its activation leads to an 
inflammatory response, therefore it must be tightly regulated.
There are 3 pathways of complement activation (classical, lectin, 
and alternative pathways) that converge into a final common pa-
thway, when a protein named factor C3 is generated. Ultimately, fac-
tor C3 cleavage results in formation of the membrane attack complex, 
the cytotoxic component of the complement system that causes cell 
lysis (Figure 1). Factor C3 plays an important role in an amplification 
loop of complement system activation.
Complement factor H (CFH) is a circulating protein that inhibits 
directly or indirectly the three complement activation pathways. It 
downregulates the system and prevents it from getting out of con-
trol. In patients with early and late AMD, many CFH polymorphisms 
have been described(11). With abnormal CFH, complement system 
downregulation is defective and excess inflammation may result. 
Addi tionally, histological analysis of drusen revealed the presence of 
complement factors and the terminal membrane attack complex(12). 
It is still unknown whether those complement factors are systemi-
cally or locally produced in the retina(13). Regardless of its origin, the 
retina with dry AMD presents with chronic subclinical local inflam-
mation that may trigger and/or sustain the damaging process(14,15).
Chronic local inflammation has also been found in other degene-
rative diseases characterized by accumulation of debris that can no 
longer be eliminated by the usual routes, such as atherosclerosis(16) 
and Alzheimer disease(17). Some components, like vitronectin and 
amyloid β, present in deposits found in those diseases, have also been 
shown in retinal drusen from eyes with AMD(12,18). It is postulated that 
the presence of such debris triggers a local inflammatory response 
that can activate the immune system(19-22). The inflammatory cells 
chro nically present in that microenvironment release cytokines that 
attract more inflammatory cells. These cells extend their processes 
through the Bruch’s membrane and basal lamina, making them thi c -
ken and creating a drusen inflammatory core. Over time, these chan-
ges may lead to impaired diffusion of waste products from hormones 
and nutrients to the RPE, including oxygen and vitamin A(7,23).
treAtMent ApproAches for Dry AMD AnD geogrAphic Atrophy
Although the complete pathological mechanisms underlying dry 
AMD have not been completely understood, new pharmacological 
treatments have emerged over the last years. Different approaches 
will be presented according to the different strategies and pharma-
cological targeting of components involved in dry AMD physiopa-
thological pathways.
1. Prevention of photoreceptors and RPE cells loss
One of the focused strategies is the prevention of photoreceptors 
and RPE cells loss, which include neuroprotection induction, oxidati-
ve damage prevention, and visual cycle modification.
1.1 Neuroprotection induction
Neuroprotective drugs aim to preserve macular function by pre-
venting apoptosis of viable RPE cells and photoreceptors. The main 
drugs under investigation will be described: Ciliary neurotrophic 
factor (CNTF), brimonidine tartrate, tandospirone, and anti-amyloid β 
antibodies.
	 •	 Ciliary	neurotrophic	factor	(CNTF) is a potent neurotrophic fac-
tor that slows down loss of photoreceptors in various animal 
models of retinal degeneration(24-27), and there are evidences 
Table 1. New drugs in the pipeline for the treatment of dry AMD and GA
Drug and mechanism of action Route of  administration Manufacturer
Prevention of photoreceptors and retinal pigment epithelim (RPE) loss
Neuroprotection
 CNTF (NT-501) Intravitreal implant (ECT) Neurotech Pharmaceuticals
 Brimonidine tartrate Intravitreal implant Allergan, Inc.
 Tandospirone Topical Alcon Laboratories, Inc.
 Anti-amyloid β antibody
 Glatiramer acetate Subcutaneous Teva Pharmaceuticals
 RN6G Intravenous Pfizer, Inc.
Oxidative damage prevention
AREDS formulation Bausch & Lomb, Inc.
Visual cycle modulators
Fenretinide Oral ReVision Therapeutics
ACU-4429 Oral Acucela, Inc.
Suppression of inflammation
Corticosteroid
Fluocinolone acetonide Intravitreal implant Alimera Sciences
Complement system inhibition
 POT-4 Intravitreal injection Potentia Pharmaceuticals
 Eculizumab Intravenous Alexion Pharmaceuticals
 ARC1905 Intravitreal injection Ophthotech Corp.
 FCFD4514S Intravitreal injection Genentech, Inc.
Damico FM, et al.
73Arq Bras Oftalmol. 2012;75(1):71-5
of its efficacy in human retinitis pigmentosa(28). NT-501 (Neuro-
tech Pharmaceuticals, USA) is an intravitreal sustained-release 
device made of a semipermeable polymer outer membrane 
which contains an internal yarn scaffold that supports live hu-
man cells (encapsulated cell technology, ECT). In this case, the 
cells are genetically engineered to produce human CNTF. ECT 
implants are distinct from other drug delivery implants in that 
they do not primarily store drug but rather produce the thera-
peutic drug to be delivered in situ. The implant is 6 mm long 
with 1 mm diameter, is inserted into the vitreous and releases 
CNTF in two different output rates for a year or longer: 5 and 
20 ng/day(26,28,29).
NT-501 was evaluated in a phase 2 clinical trial that enrolled 51 
patients with GA secondary to AMD(29). Patients were randomized to 3 
groups (low and high dose of CNTF, or sham injection) and were follo-
wed up for 1 year. At 12 months, patients who received the low- and 
high-dose implants presented a significant increase in retinal thick-
ness that may reflect increased photoreceptors metabolic activity or 
an increased number of photoreceptors. CNTF appeared to preserve 
visual acuity and a mean 0.8-letter gain was present in the high-dose 
group vs a mean 9.7-letter loss in the combined low-dose and sham 
groups. However, CNTF had no apparent effect on the progression 
of GA. Interestingly, no visual acuity loss occurred in eyes with 20/63 
or better baseline vision when treated with high-dose implants. A 
phase 3 study is planned.
	 •	 Brimonidine	tartrate (Allergan Inc., USA) is an alpha-2 adrener-
gic receptor agonist. These receptors are present in the mam-
malian retina(30) and brimonidine tartrate has been shown to 
protect retinal ganglion cells, bipolar cells, and photoreceptors 
in numerous models of experimental nerve injury, including 
re tina ischemia, ocular hypertension, retinal phototoxicity, 
and par tial optic nerve crush(31-33). Brimonidine tartrate works 
as a neuroprotectant activating some pathways inside and 
outside cells, such as increasing the expression of basic fi bro-
blast growth factor mRNA, a cytokine that delays apoptosis, 
increases the expression of proteins that regulate mitochon-
drial membrane permeability and inhibit apoptosis(34), and 
suppresses the accumulation of glutamate that causes neuronal 
cell death(35). Brimonidine tartrate is delivered by a sustained-
re lease biode gradable implant that is injected into the vitreous 
through a 22-gauge needle with the same applicator system 
used to deliver dexamethasone (Ozurdex; Allergan Inc., USA).
A 2-year phase 2 clinical trial evaluating the brimonidine im-
plant in patients with GA is under way. Patients were randomized 
to 3 treatment groups to receive the implant at 200 or 400 μg, or 
sham treatment (ClinicalTrials.gov number, NCT00658619). A second 
implant will be injected 6 months after the first one. Results of this 
study are still pending.
	 •	 Tandospirone (Alcon Laboratories Inc., USA) is a selective se ro -
tonin 1A agonist that is used as anxiolytic and antidepressant. 
In an animal model, it has been shown to protect photorecep-
tors and RPE cells from photo-oxidative stress by decreasing 
microglia activation/recruitment and complement deposition 
in the outer retinax(36). A 1-year phase 2 clinical trial including pa-
tients with GA is ongoing and two doses of topical tandospiro-
ne are being tested (ClinicalTrials.gov number, NCT00890097).
	 •	 Anti-amyloid β antibodies reduce the accumulation of amy-
loid β, a toxic byproduct which deposit is found in drusen and 
in patients with GA. Amyloid β is believed to be an important 
component of local inflammatory reaction that may contribute 
to the etiology of dry AMD. Two drugs using this strategy are 
being tested: Glatiramer acetate and RN6G.
Glatiramer acetate (Copaxone; Teva Pharmaceutical, Israel) is an 
immunomodulatory drug currently used to treat multiple sclerosis. 
Its mechanism of action is not fully elucidated but there are eviden-
ces that it suppresses T-cells, downregulates inflammatory cytokines, 
reduces amyloid β-induced retinal microglial cytotoxicity, and allows 
a neuroprotective phenotype of microglia to form(37). The analysis of 
the drusen in patients with Alzheimer disease treated with glatiramer 
acetate showed that the drug reduces drusen area(38). Specifically in 
patients with dry AMD, glatiramer acetate shrank or eliminate more 
drusen than did sham treatment(39).
RN6G (Pfizer Inc., USA) is a humanized monoclonal antibo dy 
against amyloid β that binds and sequesters amyloid β in the retinal 
pe riphery, reducing the pool of toxic species available in the macula 
and preventing its accumulation. In a mouse model of AMD, RN6G 
is administered systemically and has been shown to reduce amy loid β 
deposits in the retina. In addition, RN6G preserves animals retinal 
func tion and maintains normal RPE morphology(40). Phase 1 clinical trial 
has been completed and a phase 2 study is planned, in which AMD 
patients will be treated monthly for 6 months.
1.2 Oxidative damage prevention
AMD is a multifactorial disease caused by genetic predisposition, 
lifelong exposure to free radicals, exposure to environmental to xins, 
and low levels of naturally occurring antioxidants. Oxidative stress 
and depletion of essential micronutrients are important factors for 
AMD progression. Indeed, the AREDS formula (Bausch & Lomb Phar-
maceuticals Inc., USA) is the first effective treatment to slow the 
pro gression of the disease for patients at high risk for developing 
advan ced AMD.
AREDS is a multi-center, randomized clinical trial that included 
more than 3,000 patients over a 5-year period(4). It was designed to 
evaluate the effect of high doses of antioxidants and zinc on the 
pro gression of AMD. High levels of antioxidants (vitamin C, vita-
min E, and beta-carotene) and zinc significantly reduced the risk 
of advanced AMD and associated vision loss. AREDS showed that 
people at high risk of developing advanced AMD lowered their risk 
by about 25% when treated with the micronutrients combination. 
In the same high-risk group, which included people with interme-
diate AMD or advanced AMD in one eye but not the other eye, the 
nutrients reduced the risk of vision loss by about 19%. For patients 
who had either no AMD or early AMD, the nutrients did not provide 
an apparent benefit. 
AREDS2 is a multicenter, randomized clinical trial designed to 
assess the effects of oral supplementation of macular xanthophylls 
Figure 1. The three pathways of complement system activation (classical, lectin, and 
alternative pathways). In arrowed boxes are therapeutic agents currently investigated 
in clinical trials.
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(lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (DHA 
and EPA - eicosapentaenoic acid) on the progression to advanced 
AMD. These micronutrients are believed to function as antioxidants, 
anti-inflammatory, and anti-angiogenic agents. An additional goal 
of the study is to assess whether forms of the AREDS nutritional 
supplement with reduced zinc and/or no beta-carotene works as 
well as the original supplement in reducing the risk of progression to 
advanced AMD. Enrollment was concluded in 2008 and participants 
are being followed for approximately 5 years (ClinicalTrials.gov num-
ber, NCT00345176).
1.3 Visual cycle modification
Visual cycle modulators are pharmacologic compounds inten-
ded to modulate the visual cycle in patients with AMD. Visual cycle 
modulators essentially “slow down” the activity of the photoreceptors 
and reduce the metabolic load on these cells. So, these compounds 
may slow the deterioration by reducing the accumulation of toxic 
fluorophores (mainly A2-E) and lipofuscin, thereby preventing the 
loss of photoreceptors and RPE cells. Two drugs are currently being 
tested: Fenretinide and ACU-4429.
	 •	 Fenretinide (ReVision Therapeutics, USA) is a synthetic derivati-
ve of vitamin A, which after oral intake, strongly competes with 
vitamin A for binding to the retinol binding protein (RBP). The 
complex fenretinide-RBP is excreted in urine due to its relati-
ve ly small size and decreases the available pool of vitamin A 
avai lable for uptake at the RPE. Because A2-E biosynthesis relies 
ultimately on circulating vitamin A, in doing this, fenretinide 
inhibits the accumulation of A2-E and lipofuscin in cells of the 
RPE(41). Fenretinide has been shown to have anti-angiogenic 
and anti-inflammatory properties(42).
A multicenter, randomized phase 2 clinical trial included 246 pa -
tients with GA followed up for 1 year who were randomized to 100 mg, 
300 mg oral fenretinide, and placebo. This study showed reduction 
in lesion growth that correlated with reduction in RBP(43). In addition, 
pa tients in both treatment arms presented reduced incidence of 
choroidal neovascularization(42).
	 •	 ACU-4429 (Acucela, Inc., USA) is a small, non-retinoid molecule 
that modulates RPE65, an enzyme required to convert trans-re-
tinol to cis-retinol within the RPE. It has been shown to prevent 
the accumulation of A2-E in the mouse retina, thereby slowing 
down the visual cycle. ACU-4429 is given orally and acts selecti-
vely on the rod photoreceptors, the major source of A2-E in the 
retina.
Phase 1 clinical trial showed a dose-dependent inhibition of the b 
wave on electroretinogram. Adverse events, including dyschroma-
topsia and alteration in dark adaptation, were mild and transient(44). A 
phase 2 clinical trial is enrolling patients with dry AMD and GA (Clini-
cal Trials.gov number, NCT01002950). Patients will receive once-daily 
dosing over 3 months with 3 different doses of ACU-4429 or placebo.
2. Suppression of inflammation
There is a large amount of evidence that inflammation plays an 
important role in causing both advanced dry AMD with atrophy and 
choroidal neovascularization. Inflammatory elements are present in 
drusen, such as components of the complement system, acute-pha-
se proteins, proteins that modulate the immune response, lipofuscin, 
and dendritic cells(12,14,45-50). Therefore, it is likely that if inflammation 
could be reduced, progression of AMD could be slowed. This hypo-
thesis is being investigated with a number of approaches, including 
corticosteroid treatment and complement inhibition.
2.1 Corticosteroids
Corticosteroids are a class of chemicals that are naturally produ-
ced in the adrenal cortex and analogues of these hormones, which 
are synthesized in laboratories. Corticosteroids are involved in a wide 
range of physiologic processes including the regulation of inflam-
mation.
	 •	 Fluocinolone acetonide (Alimera Sciences, USA) is a potent cor-
ticosteroid that presented a neuroprotective effect in an ani-
mal model by dampening retinal neuroinflammation(51,52). It is 
pos tulated that the sustained-release implant, which delivers 
fluocinolone acetonide directly into the vitreous, may suppress 
retinal neuroinflammation and slow the rate of retinal degene-
ration. The implant is inserted into the vitreous via a 25-gauge 
injector. A phase 2 clinical trial enrolling patients with GA is 
un der way.
2.2 Complement system inhibitors
Several therapeutic agents involved in the complement cascade 
are under investigation.
	 •	 POT-4 (Potentia Pharmaceuticals, USA) is a synthetic peptide 
that reversibly binds complement factor C3 and inhibits acti-
vation of the complement cascade (Figure 1). POT-4 prevents 
cleavage of C3 into C3a and C3b, which eventually leads to 
the formation of the membrane attack complex. As C3 is a 
cen tral component of all complement activation pathways, its 
inhibition shuts down all downstream complement activation 
that could otherwise lead to local inflammation, tissue dama-
ge, and up-regulation of angiogenic factors. POT-4 is injected 
directly into the vitreous and forms an intravitreal blob, which 
slowly releases the drug over time. Results of a phase 1 clinical 
trial indicate that POT-4 is safe even in high doses (ClinicalTrials.
gov number, NCT00473928) and a phase 2 is being planned for 
the treatment of both dry and wet AMD to further define its 
efficacy profile.
	 •	 Eculizumab (Alexion Pharmaceuticals, USA) is a humanized IgG 
antibody that selectively inhibits the cleavage of C5 factor into 
C5a and C5b (Figure 1). Because it is a C5 inhibitor, eculizumab 
inhibits further downstream on the complement cascade than 
C3 inhibitors, thereby reducing only terminal complement 
activity, so the proximal functions of complement system 
remains intact. A phase 2 study with patients with dry AMD is 
under way (ClinicalTrials.gov number, NCT00935883).
	 •	 ARC1905 (Ophthotech Corp., USA) is an aptamer that is a po -
tent and selective inhibitor of factor C5 of the complement 
cas cade (Figure 1). The rationale is the same than that of eculi-
zumab and a phase 1 study is under way (ClinicalTrials.gov 
num ber, NCT 00950638).
	 •	 FCFD4514S (Genentech Inc., USA) is a human monoclonal an-
tibody that inhibits complement factor D, a protein involved in 
the alternative complement pathway (Figure 1). Phase 1 study 
is under way (ClinicalTrials.gov numbers, NCT 00973011).
CONCLUSION
Currently, the only approved treatment for dry AMD is the use 
of AREDS formulation. However, this multivitamin complex does 
not prevent AMD and its positive effects are modest as it only slows 
down the progression for patients at high risk for advanced AMD. 
Many advances in the fields of epidemiology, pathogenesis, and 
genetics have been produced in the last decade. Novel treatment 
strategies are under investigation for the treatment of dry AMD and 
GA, such as prevention of photoreceptors and RPE cells loss, and 
suppression of inflammation. In the near future, it is likely that the 
treatment of dry AMD will be a combination of different drugs that 
will target the different pathways involved in the development and 
progression of AMD.
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